Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

BUY
$11.12 - $22.2 $1,456 - $2,908
131 Added 1.03%
12,880 $147,000
Q1 2023

May 08, 2023

BUY
$18.7 - $23.07 $14,810 - $18,271
792 Added 6.62%
12,749 $256,000
Q4 2022

Feb 07, 2023

SELL
$18.12 - $27.32 $123,650 - $186,431
-6,824 Reduced 36.33%
11,957 $271,000
Q3 2022

Nov 01, 2022

BUY
$16.98 - $25.54 $5,348 - $8,045
315 Added 1.71%
18,781 $352,000
Q2 2022

Aug 04, 2022

BUY
$13.15 - $20.45 $101,386 - $157,669
7,710 Added 71.68%
18,466 $344,000
Q1 2022

May 09, 2022

BUY
$14.54 - $21.5 $13,420 - $19,844
923 Added 9.39%
10,756 $194,000
Q4 2021

Feb 07, 2022

BUY
$20.24 - $36.01 $10,018 - $17,824
495 Added 5.3%
9,833 $211,000
Q3 2021

Nov 04, 2021

BUY
$26.01 - $38.22 $6,372 - $9,363
245 Added 2.69%
9,338 $299,000
Q2 2021

Aug 06, 2021

BUY
$29.97 - $37.17 $30,209 - $37,467
1,008 Added 12.47%
9,093 $280,000
Q1 2021

May 06, 2021

BUY
$29.24 - $42.03 $70,848 - $101,838
2,423 Added 42.79%
8,085 $272,000
Q4 2020

Feb 09, 2021

BUY
$35.35 - $50.67 $91,591 - $131,285
2,591 Added 84.37%
5,662 $205,000
Q3 2020

Nov 10, 2020

SELL
$35.98 - $47.66 $4,569 - $6,052
-127 Reduced 3.97%
3,071 $113,000
Q2 2020

Aug 06, 2020

SELL
$45.06 - $67.74 $2,027 - $3,048
-45 Reduced 1.39%
3,198 $144,000
Q1 2020

May 11, 2020

BUY
$40.01 - $73.97 $26,446 - $48,894
661 Added 25.6%
3,243 $154,000
Q4 2019

Feb 05, 2020

BUY
$37.13 - $74.62 $11,510 - $23,132
310 Added 13.64%
2,582 $184,000
Q3 2019

Nov 12, 2019

BUY
$39.36 - $76.8 $16,098 - $31,411
409 Added 21.95%
2,272 $89,000
Q2 2019

Aug 08, 2019

SELL
$52.76 - $82.19 $167,882 - $261,528
-3,182 Reduced 63.07%
1,863 $146,000
Q1 2019

Apr 26, 2019

BUY
$27.39 - $68.41 $17,748 - $44,329
648 Added 14.74%
5,045 $301,000
Q4 2018

Feb 08, 2019

SELL
$22.8 - $33.93 $1,185 - $1,764
-52 Reduced 1.17%
4,397 $120,000
Q3 2018

Nov 13, 2018

BUY
$29.75 - $43.08 $132,357 - $191,662
4,449 New
4,449 $162,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.